Nutra Pharma appeared in a feature article in today’s Washington Post entitled “Sharing the Pain”, which discussed a novel new website called RareShare that works to connect patients with rare medical disorders. One of the co-founders, David Isserman, mentioned that his work with Nutra Pharma and in particular, our work with the rare disorder Adrenomyeloneuropathy (AMN), helped him recognize the need for such a site. Click here to view the full article online and to join David in a live online discussion on WashingtonPost.com starting today at 12PM Eastern.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Receives Mention in the Washington Post", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website